Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma
Brief Summary: This randomized phase II trial is studying sorafenib and interferon alfa-2b to see how well they work compared to sorafenib alone in treating patients with metastatic kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib and interferon alfa-2b may also block blood flow to the tumor. Giving sorafenib together with interferon alfa-2b may kill more tumor cells.


Options:
A: Arm Label: Sorafenib Tosylate; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate, Other: Laboratory Biomarker Analysis | Arm Label: Sorafenib Tosylate, Recombinant interferon alfa-2b; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate, Biological: Recombinant Interferon Alfa-2b, Other: Laboratory Biomarker Analysis | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Sorafenib Tosylate, Sorafenib Tosylate, Recombinant interferon alfa-2b | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Sorafenib Tosylate, Recombinant interferon alfa-2b | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Sorafenib Tosylate, Sorafenib Tosylate, Recombinant interferon alfa-2b
B: Arm Label: First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg | Intervention Type: DRUG; Name: Interferon; Assigned to Arm(s): First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg
C: Arm Label: Arm I (sunitinib malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Sunitinib Malate | Arm Label: Arm II (cabozantinib s-malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Drug: Cabozantinib S-malate, Procedure: Computed Tomography | Arm Label: Arm III (crizotinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Crizotinib | Arm Label: Arm IV (savolitinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Savolitinib | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: PROCEDURE; Name: Bone Scan; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm II (cabozantinib s-malate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Crizotinib; Assigned to Arm(s): Arm III (crizotinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm I (sunitinib malate)
D: Arm Label: Interferon; Type: EXPERIMENTAL; Interventions: Biological: recombinant interferon alfa | Arm Label: Interferon + bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Biological: recombinant interferon alfa | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Interferon + bevacizumab | Intervention Type: BIOLOGICAL; Name: recombinant interferon alfa; Assigned to Arm(s): Interferon, Interferon + bevacizumab

Answer: A